Litwin A, Flanagan M, Entis G, Gottschlich G, Esch R, Gartside P, Michael J G
Department of Molecular Genetics, College of Medicine, University of Cincinnati, Ohio, USA.
Ann Allergy Asthma Immunol. 1996 Aug;77(2):132-8. doi: 10.1016/S1081-1206(10)63499-0.
Oral allergen immunotherapy with conventional allergens has not been a useful mode of treatment because of the lack of potency of allergens when administered by this route.
To study the immunologic potency of short ragweed pollen extracts microencapsulated by a new technique administered orally to short ragweed pollen-sensitive humans and to establish the dose of oral microencapsulated short ragweed pollen extract required for these effects.
Nine short ragweed pollen-sensitive patients were treated with a new oral agent for immunotherapy, microencapsulated short ragweed pollen extract, in an open study. The effectiveness of this treatment was determined by comparison to a group of nine matched short ragweed pollen-sensitive patients who received no treatment. Treated patients developed high titers of short ragweed-specific IgG and IgE antibodies and their expected seasonal increase in IgE antibodies was regulated. The dose of microencapsulated short ragweed pollen extract required to achieve these effects was only slightly higher than the dose of short ragweed pollen extract used in high dose subcutaneous immunotherapy. Furthermore, this dose was achieved in 7 weeks. There were no side effects other than mild gastrointestinal ones. The nine treated patients fared clinically better during the ragweed season than the untreated patients in this open study.
This study suggests that allergens microencapsulated by this new technique may make oral immunotherapy a practical mode of treatment.
由于通过口服途径给予传统过敏原时其效力不足，口服过敏原免疫疗法一直不是一种有效的治疗方式。
研究采用新技术微囊化的豚草花粉提取物口服给予豚草花粉敏感人群后的免疫效力，并确定产生这些效应所需的口服微囊化豚草花粉提取物的剂量。
在一项开放性研究中，9名豚草花粉敏感患者接受了一种用于免疫疗法的新型口服制剂——微囊化豚草花粉提取物的治疗。通过与一组9名匹配的未接受治疗的豚草花粉敏感患者进行比较，来确定这种治疗的有效性。接受治疗的患者产生了高滴度的豚草特异性IgG和IgE抗体，并且他们预期的IgE抗体季节性增加得到了调节。实现这些效应所需的微囊化豚草花粉提取物的剂量仅略高于高剂量皮下免疫疗法中使用的豚草花粉提取物的剂量。此外，该剂量在7周内即可达到。除了轻微的胃肠道反应外，没有其他副作用。在这项开放性研究中，9名接受治疗的患者在豚草季节的临床情况比未接受治疗的患者更好。
这项研究表明，采用这种新技术微囊化的过敏原可能使口服免疫疗法成为一种切实可行的治疗方式。
